313
Views
2
CrossRef citations to date
0
Altmetric
Research Article

Polygonatum polysaccharide modified montmorillonite/chitosan/glycerophosphate composite hydrogel for bone tissue engineering

, , , , , , , , , , , & ORCID Icon show all
Pages 1176-1187 | Received 23 Apr 2021, Accepted 22 Jul 2021, Published online: 24 Aug 2021
 

Abstract

The stiffness and gelation temperature of thermo-responsive chitosan (CS), glycerophosphate (GP) hydrogel is not enough for differentiation of BMSCs and injecting use in bone defect repair. To improve these weaknesses, a kind of injectable hydrogel (PMCG) was prepared with Chitosan (CS), glycerophosphate (GP), polygonatum polysaccharide modified montmorillonite (PMMT). The gelation temperature of CS/GP (CG) hydrogel was 42 °C, the maximum mechanical strength was 1061 Pa. with the amount of PMMT increased, the gelation temperature decreased to 28 °C, and the maximum stiffness increased to 6789 Pa. At the same time, with the addition of PMMT, the swelling property of hydrogel was improved. The cytocompatibility of PMCG decreased than CG which maybe result from the poor cytocompatibility of montmorillonite, but it was improved with increasing amount of PMMT, which indicated the cell proliferation promoting effect coming from polygonatum polysaccharide. The SEM-EDX exhibited that these hydrogels possessed excellent morphological characteristics and could promote mineralization in simulated body fluid (SBF) solution, PMCG-2 Ca/P has a Ca/P ratio of 1.63 ± 0.04, which is similar to the ratio of human bone mineral (Ca/P ratio of 1.55–1.75). The cell viability confirmed the application availability of the hydrogel. In light of the effect on osteoblasts maturation promoting effect and decrease of osteoclast of polygonatum polysaccharide. We come to the conclusion that it is an effective strategy to improve the mechanic strength and gelation temperature, and keep the osteogenesis promoting effect at the same time.

Graphical Abstract

Additional information

Funding

This work was supported by the MRSEC Program of the National Natural Science Foundation of China [NO: 81560737], Guangxi Provincial Natural Science Fund of China (project [2016GXNSFAA380234]), National Natural Science Foundation of China [31860250], Natural Science Foundation of Gansu Province [18JR3RA148], Fundamental Research Funds for Key Laboratory of Drug Screening and Deep Processing for Traditional Chinese and Tibetan Medicine of Gansu Province [20180801].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.